Resource Summary Report

Generated by dkNET on Sep 1, 2026

OKT 3

RRID:CVCL_2665
Type: Cell Line

Proper Citation

ECACC Cat# 86022706, RRID:CVCL_2665

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2665

Proper Citation: ECACC Cat# 86022706, RRID:CVCL_2665

Description: Cell line OKT 3 is a Hybridoma with a species of origin Mus musculus (Mouse)

Defining Citation: PMID:314668

Comments: Anecdotal: OKT3 was the first monoclonal antibody to be approved for clinical use in humans., Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized teplizumab (MGA031) therapeutic antibody., Biotechnology: The monoclonal antibody produced by this hybridoma was used as an immunosuppressant drug under the name Muromonab-CD3 (Orthoclone OKT3)., Group: Patented cell line.

Category: Hybridoma

Organism: Mus musculus (Mouse)

Name: OKT 3

Synonyms: OKT3

Cross References: CLO:CLO_0008252, CLDB:cl5239, ABCD:ABCD_AC852, ATCC:CRL-8001, BCRC:60154, CCRID:3101ETCHYB58, CLS:300499, ECACC:86022706, IZSLER:BS Hy 12, NCBI_Iran:H104, TKG:TKG 0235, Wikidata:Q54931950

ID: CVCL_2665

Vendor: ECACC

Catalog Number: 86022706

Hierarchy: cvcl_3412

Record Creation Time: 20250130T072550+0000

Record Last Update: 20260830T001655+0000

Ratings and Alerts

No rating or validation information has been found for OKT 3.

No alerts have been found for OKT 3.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Van Pelt S, et al. (2025) Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b. Cancer immunology research, 13(11), 1732.

Ducoin K, et al. (2022) Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. Oncoimmunology, 11(1), 2046931.

Marin E, et al. (2019) Human Tolerogenic Dendritic Cells Regulate Immune Responses through Lactate Synthesis. Cell metabolism, 30(6), 1075.

Picarda E, et al. (2019) Cross-Reactive Donor-Specific CD8+ Tregs Efficiently Prevent Transplant Rejection. Cell reports, 29(13), 4245.